PL2094663T3 - Pochodne pirydyny do leczenia zaburzeń matabolicznych związanych z insulinoopornością lub hiperglikemią - Google Patents

Pochodne pirydyny do leczenia zaburzeń matabolicznych związanych z insulinoopornością lub hiperglikemią

Info

Publication number
PL2094663T3
PL2094663T3 PL07826467T PL07826467T PL2094663T3 PL 2094663 T3 PL2094663 T3 PL 2094663T3 PL 07826467 T PL07826467 T PL 07826467T PL 07826467 T PL07826467 T PL 07826467T PL 2094663 T3 PL2094663 T3 PL 2094663T3
Authority
PL
Poland
Prior art keywords
hyperglycemia
treatment
insulin resistance
metabolic disorders
disorders related
Prior art date
Application number
PL07826467T
Other languages
English (en)
Polish (pl)
Inventor
Nabajyoti Deka
Sivaramakrishnan Hariharan
Swapnil Ramesh Bajare
Rosalind Adaikalasamy Marita
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of PL2094663T3 publication Critical patent/PL2094663T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL07826467T 2006-09-21 2007-09-20 Pochodne pirydyny do leczenia zaburzeń matabolicznych związanych z insulinoopornością lub hiperglikemią PL2094663T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84619406P 2006-09-21 2006-09-21
US87567206P 2006-12-18 2006-12-18
EP07826467A EP2094663B1 (en) 2006-09-21 2007-09-20 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
PCT/IB2007/053811 WO2008035305A2 (en) 2006-09-21 2007-09-20 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia

Publications (1)

Publication Number Publication Date
PL2094663T3 true PL2094663T3 (pl) 2011-07-29

Family

ID=39048032

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07826467T PL2094663T3 (pl) 2006-09-21 2007-09-20 Pochodne pirydyny do leczenia zaburzeń matabolicznych związanych z insulinoopornością lub hiperglikemią

Country Status (19)

Country Link
US (5) US8030324B2 (enExample)
EP (2) EP2094663B1 (enExample)
JP (2) JP5331953B2 (enExample)
KR (2) KR20090075827A (enExample)
AR (2) AR062941A1 (enExample)
AT (1) ATE496890T1 (enExample)
AU (2) AU2007298539B2 (enExample)
BR (2) BRPI0718510A2 (enExample)
CA (2) CA2663901A1 (enExample)
DE (1) DE602007012299D1 (enExample)
DK (1) DK2094663T3 (enExample)
IL (2) IL197695A0 (enExample)
MX (2) MX2009002905A (enExample)
NZ (2) NZ576197A (enExample)
PL (1) PL2094663T3 (enExample)
PT (1) PT2094663E (enExample)
RU (2) RU2448093C2 (enExample)
TW (2) TW200820970A (enExample)
WO (2) WO2008035305A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013117963A1 (en) 2012-02-09 2013-08-15 Piramal Enterprises Limited Stable oral tablet dosage form of an antidiabetic compound
PE20160664A1 (es) 2013-06-27 2016-07-09 Pfizer Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
WO2014207508A1 (en) * 2013-06-27 2014-12-31 Piramal Enterprises Limited Pyridyl compound suitable for the treatment of metabolic disorders
EA028614B1 (ru) * 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
MX2023005371A (es) 2020-11-09 2023-05-22 Eisai R&D Man Co Ltd Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084085A (en) * 1986-08-20 1992-01-28 Fmc Corporation Herbicidal aryloxyphenyltriazolinones and related compounds
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
NZ515087A (en) * 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
WO2001000579A1 (en) * 1999-06-30 2001-01-04 Tularik Inc. COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
HK1052351B (en) * 2000-06-28 2006-11-03 Japan Tobacco Inc. Benzothiazolyl ppar-gamma modulators
CA2526204A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US8188277B2 (en) * 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
RU2383533C2 (ru) * 2004-10-04 2010-03-10 Ф.Хоффманн-Ля Рош Аг Алкилированные производные пиридина в качестве ингибиторов 11-бета при диабете

Also Published As

Publication number Publication date
WO2008035305A8 (en) 2009-03-12
US20120309786A1 (en) 2012-12-06
DK2094663T3 (da) 2011-04-26
US8030324B2 (en) 2011-10-04
US20100022554A1 (en) 2010-01-28
JP2010504322A (ja) 2010-02-12
JP2010504321A (ja) 2010-02-12
TW200817364A (en) 2008-04-16
BRPI0718510A2 (pt) 2013-11-19
CA2663901A1 (en) 2008-03-27
WO2008035305A2 (en) 2008-03-27
AR062941A1 (es) 2008-12-17
AU2007298539A1 (en) 2008-03-27
MX2009002906A (es) 2009-06-30
AU2007298539B2 (en) 2013-05-02
AR062940A1 (es) 2008-12-17
IL197695A0 (en) 2009-12-24
MX2009002905A (es) 2009-06-19
EP2094663B1 (en) 2011-01-26
AU2007298540A1 (en) 2008-03-27
US20090247574A1 (en) 2009-10-01
US8269010B2 (en) 2012-09-18
KR20090075827A (ko) 2009-07-09
IL197694A0 (en) 2009-12-24
NZ576197A (en) 2011-12-22
KR20090074775A (ko) 2009-07-07
EP2094663A2 (en) 2009-09-02
RU2009114545A (ru) 2010-10-27
CA2663943A1 (en) 2008-03-27
AU2007298540B2 (en) 2013-02-21
EP2094687A1 (en) 2009-09-02
DE602007012299D1 (de) 2011-03-10
JP5331953B2 (ja) 2013-10-30
NZ576196A (en) 2011-12-22
RU2448093C2 (ru) 2012-04-20
WO2008035305A3 (en) 2008-06-12
US20110312970A1 (en) 2011-12-22
BRPI0717106A2 (pt) 2013-10-08
ATE496890T1 (de) 2011-02-15
PT2094663E (pt) 2011-04-19
RU2460729C2 (ru) 2012-09-10
US8349862B2 (en) 2013-01-08
RU2009114544A (ru) 2010-10-27
US20130040988A1 (en) 2013-02-14
WO2008035306A1 (en) 2008-03-27
TW200820970A (en) 2008-05-16

Similar Documents

Publication Publication Date Title
IL196586A0 (en) Substituted spiroketal derivatives and use thereof as therapeutic drug for diabetes
IL201537A0 (en) Heteroaryl substituted pyarzole derivatives useful for treating hyper- proliferative disorders and diseases associated with angiogenesis
IL197694A0 (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
IL202515A (en) Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases
IL208246A0 (en) Polysubstituted 2-aryl-6-phenyl-imidazo[1,2-a]pyridine derivatives, and preparation and therapeutic use thereof
WO2009055331A3 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL198112A0 (en) 3-aminoimidazo [1,2-a]pyridine derivatives having an sglt1-and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL195203A0 (en) Compounds for the treatment of metabolic disorders
ZA201007127B (en) Carboxamide compounds for the treatment of metabolic disorders
GB0619860D0 (en) Treatment of insulin resistance and disorders associated therewith
IL194189A0 (en) Combination treatment of metabolic disorders
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
IL199829A0 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
ZA200805645B (en) Compounds for the treatment of metabolic disorders
TWI348910B (en) Composition for controlling blood glucose and method thereof
ZA200904281B (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
IL201119A0 (en) Methods and compositions of derivatives of probucol for the treatment of diabetes
IL195392A0 (en) Compounds for the treatment of metabolic disorders
ZA200805595B (en) Compounds for the treatment of metabolic disorders
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
IL206667A0 (en) 2-HETEROAROYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
HK1135689A (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
IL200192A0 (en) Composition useful for the treatment of type 2 diabetes